AstraZeneca Sponsored Symposium

Sponsored Breakfast Symposium

28 September 2018,07:15 – 08:15 

Tumour first: a novel approach to BRCA1/2 mutation testing in patients with ovarian cancer
Bojana Djordjevic, MD, FRCPC, FCAP
Gynecologic Pathologist, Division of Anatomic Pathology, Sunnybrook Health Sciences Centre;
Associate Professor, Department of Laboratory Medicine and Pathobiology, University of Toronto

Learning objectives
At the end of this session participants will be able to:

  • Summarize the clinical relevance of identifying ovarian carcinoma patients with BRCA 1/2 mutations
  • Provide an overview of germline versus tumour-based BRCA1/2 mutation testing; differences and limitations
  • Identify the emerging new role of the pathology laboratory in tumour BRCA1/2 mutation testing
  • Compare and contrast BRCA1/2 mutation testing protocols with other clinically implemented tumour first testing models

The seminar will describe germline and tumour first models of testing, outlining how the role of the pathologist is evolving within these workflows. Germline versus somatic BRCA1/2 mutation testing protocols and consent issues will be reviewed. Solutions to logistical challenges will be discussed to help align tumour first and germline testing protocols for BRCA1/2 mutation testing in Ontario. Discussion with the audience on specific implementation challenges faced in Ontario labs will end the session.